Contract Manufacturing, Solid Dosage

CordenPharma will build a clinical trial development facility for manufacture of oral solid dosage drug products at its Plankstadt facility near Heidelberg, Germany.

Hovione will invest $170 million in new capacity and capabilities in Portugal, Ireland, and New Jersey

CMDO Piramal Pharma Solutions held a grand opening at a facility they acquired in Sellersville, PA.

The renovations are expected to be completed by Feb. 1, 2021 and, upon completion, Aphena will move its corporate headquarters to the new location.

Experts at Hovione describe progress being made in understanding how to optimize continuous processes for oral solid-dosage drug products.

Careful design, planning, and record keeping are needed for cleaning and changeover in multiproduct pharmaceutical facilities.

Establishing OEL data and ensuring appropriate engineering controls are crucial aspects of safe handling.

The evolution of CDMOs has led to increased investment in new technologies, capabilities, and expertise.

The expansion of Lonza’s Tampa site includes development and manufacturing capabilities for oral solid-dose drugs.

Expansion at the Eberbach, Germany facility includes two Vegicap encapsulation lines, printing, inspection, and packaging capabilities.

Catalent announces investment for its Zydis ODT technology, offering increased drug load and taste-masking capabilities.

The $252-million acquisition is expected to strengthen Cambrex’s position as a small-molecule CDMO across the drug lifecycle.

Bioprocessing and manufacturing events bioLIVE and BioProduction Congress will take place as one event adjacent to CPhI Worldwide in Frankfurt, Germany, on November 5–7, 2019.

The acquisition will place Cambrex into the finished dosage form CDMO market.

As more continuous processes move toward commercialization, users and equipment vendors are working to speed changeovers and address other needs.

A new suite for the encapsulation of highly potent drugs will be added.

As part of Recipharm’s ongoing initiative to improve profitability and competitiveness, a decision has been made to end operations in Stockholm and Höganäs.

Recent acquisitions are creating CDMOs with scale that rivals global bio/pharma.

CordenPharma will expand development capacity for small molecules, peptides, and carbohydrates at its Liestal, Switzerland site

Predicted areas of growth include flow chemistry, fermentation, repatriation of overseas funds, oncology, and API/product integration, but the rate of change is unclear.

Mergers and acquisitions are positive for the CDMO industry, but there is a downside.

Additional reactor capacity and a wastewater processing plant increase API manufacturing capacity at the Cambrex site in Kalskoga, Sweden.

Catalent expands the scope of the OptiForm Solution Suite to bridge gap from late-stage discovery to Phase I trials.

Pfizer’s new format of ibuprofen (AdvilR Liqui-GelsR Minis) uses Catalent’s softgel technology to deliver the formulation in a more concentrated fill, resulting in smaller capsules.

Cambrex announces expansions of its North Carolina API pilot plant and Kalskoga, Sweden large-scale manufacturing facility.

The company invested approximately $26 million to update its sterile pharmaceutical and development service suites.

Catalent announces a development agreement with JOT to evaluate softgel options for a resveratrol drug candidate.

Catalent adds two softgel facilities and packaging capabilities with acquisition of Canada-based Accucaps.

Bio/pharmaceutical contract service provides continue to invest in development, facility upgrades, technological advancement, and mergers and acquisitions.

Hovione will operate a commercial-scale continuous manufacturing facility in New Jersey as part of an agreement with Vertex Pharmaceuticals.